Skip to main content
Erschienen in: Archives of Dermatological Research 10/2007

01.03.2007 | Original Paper

Angiogenic activity in patients with psoriasis is significantly decreased by Goeckerman’s therapy

verfasst von: C. Andrys, L. Borska, D. Pohl, Z. Fiala, K. Hamakova, J. Krejsek

Erschienen in: Archives of Dermatological Research | Ausgabe 10/2007

Einloggen, um Zugang zu erhalten

Abstract

Goeckerman’s therapy (GT) of psoriasis is based on daily application of pharmacy grade coal tar on affected skin with subsequent exposure to UV light. Goeckerman’s therapy is still the first line therapy of psoriasis in the Czech Republic because of its low cost and long-term efficacy. Disturbances in angiogenic activity are characteristic for the immunopathogenesis of psoriasis. An abnormal spectrum of cytokines, growth factors and proangiogenic mediators is produced by keratinocytes and inflammatory cells in patients suffering from the disease. The aim of this study was to evaluate the influence of GT of psoriasis on angiogenic activities by comparing serum levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in 44 patients with psoriasis in peripheral blood samples collected before and after therapy. Forty otherwise healthy blood donors serve as a control group. The efficacy of GT was delineated by psoriasis area and severity index (PASI). The disease activity was significantly diminished by GT (P < 0.001). The serum levels of both VEGF and bFGF were statistically significantly correlated to PASI value in patients before the treatment by GT. The serum levels of VEGF (329.4 ± 125.5 pg/ml) and bFGF (10.2 ± 5.04 pg/ml) in patients before GT were significantly higher than those measured in healthy blood donors (VEGF 236.4 ± 55.9 pg/ml, bFGF 7.3 ± 3.7 pg/ml). The serum levels of both VEGF and bFGF were significantly diminished by GT. The level of VEGF dropped from 329.4 ± 125.5 pg/ml before GT to 278.5 ± 109.9 pg/ml after GT (P = 0.0042) and the level of bFGF fell from 10.2 ± 5.04 to 7.78 ± 4.5 pg/ml (P = 0.019). Comparing to healthy controls, the serum level of bFGF in psoriasis patients was normalised (P = 0.5723) after GT. In contrast, the serum level of VEGF remained significantly increased in psoriasis patients after GT in comparison with healthy blood donors (P = 0.0319). In conclusion, we found that the angiogenic potential which is abnormally increased in patients with psoriasis is significantly alleviated by GT.
Literatur
1.
Zurück zum Zitat Arbiser JL, Govindarajan B, Battle TE, Lynch R, Frank DA, Ushio-Fukai M, Perry BN, Stern DF, Bowden GT, Liu A, Klein E, Kolodziejski PJ, Eissa NT, Hossain CF, Nagle DG (2006) Carbazole is a naturally occurring inhibitor of angiogenesis and inflammation isolated from antipsoriatic coal tar. J Invest Dermatol 126:1396–1402PubMedCrossRef Arbiser JL, Govindarajan B, Battle TE, Lynch R, Frank DA, Ushio-Fukai M, Perry BN, Stern DF, Bowden GT, Liu A, Klein E, Kolodziejski PJ, Eissa NT, Hossain CF, Nagle DG (2006) Carbazole is a naturally occurring inhibitor of angiogenesis and inflammation isolated from antipsoriatic coal tar. J Invest Dermatol 126:1396–1402PubMedCrossRef
2.
Zurück zum Zitat Beissert S, Cavazzana I, Mascia F, Meroni P, Pastore S, Tessari G, Girolomoni G (2006) Mechanisms of immune-mediated skin diseases: an overview. Clin Exp Rheumatol 24(1Suppl 40):S1–S6PubMed Beissert S, Cavazzana I, Mascia F, Meroni P, Pastore S, Tessari G, Girolomoni G (2006) Mechanisms of immune-mediated skin diseases: an overview. Clin Exp Rheumatol 24(1Suppl 40):S1–S6PubMed
3.
Zurück zum Zitat Bhushan M, McLaughlin B, Weiss JB, Griffiths CEM (1999) Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 141:1054–1060PubMedCrossRef Bhushan M, McLaughlin B, Weiss JB, Griffiths CEM (1999) Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 141:1054–1060PubMedCrossRef
4.
Zurück zum Zitat Bhushan M, Young HS, Brenchley PEC, Griffiths CEM (2002) Recent advances in cutaneous angiogenesis. Br J Dermatol 147:418–425PubMedCrossRef Bhushan M, Young HS, Brenchley PEC, Griffiths CEM (2002) Recent advances in cutaneous angiogenesis. Br J Dermatol 147:418–425PubMedCrossRef
5.
Zurück zum Zitat Bielenberg DR, Bucana CD, Sanchez R, Donawho CHK, Kripke ML, Fidler IJ (1998) Molecular regulation of UVB-induced cutaneous angiogenesis. J Invest Dermatol 111:864–872PubMedCrossRef Bielenberg DR, Bucana CD, Sanchez R, Donawho CHK, Kripke ML, Fidler IJ (1998) Molecular regulation of UVB-induced cutaneous angiogenesis. J Invest Dermatol 111:864–872PubMedCrossRef
6.
Zurück zum Zitat Bovenschen HJ, Seyger MM, van de Kerkhof PC (2005) Plaque psoriasis vs. atopic dermatitis and lichen planus: a comparison for lesional T-cell subsets, epidermal proliferation and differentiantion. Br J Dermatol 153:72–78PubMedCrossRef Bovenschen HJ, Seyger MM, van de Kerkhof PC (2005) Plaque psoriasis vs. atopic dermatitis and lichen planus: a comparison for lesional T-cell subsets, epidermal proliferation and differentiantion. Br J Dermatol 153:72–78PubMedCrossRef
7.
Zurück zum Zitat Chen CH, Poucher SM, Lu J, Henry PD (2004) Fibroblast growth factor 2: from laboratory evidence to clinical application. Curr Vasc Pharmacol 2:33–43PubMedCrossRef Chen CH, Poucher SM, Lu J, Henry PD (2004) Fibroblast growth factor 2: from laboratory evidence to clinical application. Curr Vasc Pharmacol 2:33–43PubMedCrossRef
8.
Zurück zum Zitat Creamer D, Sullivan D, Bicknell R, Barker J (2002) Angiogenesis in psoriasis. Angiogenesis 5:231–236PubMedCrossRef Creamer D, Sullivan D, Bicknell R, Barker J (2002) Angiogenesis in psoriasis. Angiogenesis 5:231–236PubMedCrossRef
9.
Zurück zum Zitat Cuevas P, Arrazola JM (2005) Dobesilate in the treatment of plaque psoriasis. Eur J Med Res 10:373–376PubMed Cuevas P, Arrazola JM (2005) Dobesilate in the treatment of plaque psoriasis. Eur J Med Res 10:373–376PubMed
10.
12.
Zurück zum Zitat Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O (2003) Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 47:149–161PubMed Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O (2003) Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 47:149–161PubMed
13.
Zurück zum Zitat Feldman SR (2005) Where has Goeckerman treatment gone? J Dermatolog Treat 16:73–74PubMed Feldman SR (2005) Where has Goeckerman treatment gone? J Dermatolog Treat 16:73–74PubMed
14.
Zurück zum Zitat Ferrara N (1999) Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 56:794–814PubMedCrossRef Ferrara N (1999) Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 56:794–814PubMedCrossRef
16.
Zurück zum Zitat Goeckerman WH (1925) Treatment of psoriasis. Northwest Med 24:229–231 Goeckerman WH (1925) Treatment of psoriasis. Northwest Med 24:229–231
17.
Zurück zum Zitat Gupta AK, Langley R, Poulin Y, Lui H, Searles G, Carey W, Toole J, Inniss K (2004) Pathogenesis of psoriasis and current challenges. J Cutan Med Surg 8(Suppl):3–7PubMedCrossRef Gupta AK, Langley R, Poulin Y, Lui H, Searles G, Carey W, Toole J, Inniss K (2004) Pathogenesis of psoriasis and current challenges. J Cutan Med Surg 8(Suppl):3–7PubMedCrossRef
18.
Zurück zum Zitat Kerbel RS (2000) Tumor angiogenesis: past, present and the near future. Carcinogenesis 21:505–515PubMedCrossRef Kerbel RS (2000) Tumor angiogenesis: past, present and the near future. Carcinogenesis 21:505–515PubMedCrossRef
19.
Zurück zum Zitat Lebwohl M, Ali S (2001) Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 45:487–498PubMedCrossRef Lebwohl M, Ali S (2001) Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 45:487–498PubMedCrossRef
20.
Zurück zum Zitat Lee E, Koo J (2005) Modern modified ‘ultra’ Goeckerman therapy: a PASI assessment of a very effective therapy for psoriasis resistant to both prebiologic and biologic therapies. J Dermatolog Treat 16:102–107PubMed Lee E, Koo J (2005) Modern modified ‘ultra’ Goeckerman therapy: a PASI assessment of a very effective therapy for psoriasis resistant to both prebiologic and biologic therapies. J Dermatolog Treat 16:102–107PubMed
21.
Zurück zum Zitat Leong TT, Fearon U, Veale DJ (2005) Angiogenesis in psoriasis and psoriatic arthritis: clues to disease pathogenesis. Curr Rheumatol Rep 7:325–329PubMed Leong TT, Fearon U, Veale DJ (2005) Angiogenesis in psoriasis and psoriatic arthritis: clues to disease pathogenesis. Curr Rheumatol Rep 7:325–329PubMed
22.
Zurück zum Zitat Nielsen HJ, Christensen IJ, Svendsen MN, Hansen U, Werther K, Brünner N, Petersen LJ, Kristensen JK (2002) Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm Res 51:563–567PubMedCrossRef Nielsen HJ, Christensen IJ, Svendsen MN, Hansen U, Werther K, Brünner N, Petersen LJ, Kristensen JK (2002) Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm Res 51:563–567PubMedCrossRef
23.
Zurück zum Zitat Powers CJ, McLeskey SW, Wellstein A (2000) Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 7:165–197PubMedCrossRef Powers CJ, McLeskey SW, Wellstein A (2000) Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 7:165–197PubMedCrossRef
24.
Zurück zum Zitat Smolej L, Andrys C, Maisnar V, Pour L, Maly J (2005) Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders. Acta Medica (Hradec Kralove) 48:57–58 Smolej L, Andrys C, Maisnar V, Pour L, Maly J (2005) Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders. Acta Medica (Hradec Kralove) 48:57–58
25.
Zurück zum Zitat Staton CA, Stribbling SM, Tazzyman S, Hughes R, Brown NJ, Lewis CE (2004) Current methods for assaying angiogenesis in vitro and in vivo. Int J Exp Pathol 85:233–248PubMedCrossRef Staton CA, Stribbling SM, Tazzyman S, Hughes R, Brown NJ, Lewis CE (2004) Current methods for assaying angiogenesis in vitro and in vivo. Int J Exp Pathol 85:233–248PubMedCrossRef
27.
Zurück zum Zitat Tille JC, Wood J, Mandriota SJ, Schnell C, Ferrari S, Mestan J, Zhu Z, Witte L, Pepper MS (2001) Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. J Pharmacol Exp Ther 299:1073–1085PubMed Tille JC, Wood J, Mandriota SJ, Schnell C, Ferrari S, Mestan J, Zhu Z, Witte L, Pepper MS (2001) Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. J Pharmacol Exp Ther 299:1073–1085PubMed
28.
Zurück zum Zitat Yano K, Kadoya K, Kajiya K, Hong YK, Detmar M (2005) Ultraviolet B irradiation of human skin induces an angiogenic switch that is mediated by upregulation of vascular endothelial growth factor and by downregulation of thrombospondin-1. Br J Dermatol 152:115–121PubMedCrossRef Yano K, Kadoya K, Kajiya K, Hong YK, Detmar M (2005) Ultraviolet B irradiation of human skin induces an angiogenic switch that is mediated by upregulation of vascular endothelial growth factor and by downregulation of thrombospondin-1. Br J Dermatol 152:115–121PubMedCrossRef
29.
Zurück zum Zitat Young HS, Summers AM, Bhushan M, Brenchley PE, Griffiths CE (2004) Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. J Invest Dermatol 122:209–215PubMedCrossRef Young HS, Summers AM, Bhushan M, Brenchley PE, Griffiths CE (2004) Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. J Invest Dermatol 122:209–215PubMedCrossRef
30.
Zurück zum Zitat Young HS, Summers AM, Read IR, Fairhust DA, Plant DJ, Campalani E, Smith CH, Barker JN, Detmar MJ, Brenchley PE, Griffiths CE (2006) Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol 126:453–459PubMedCrossRef Young HS, Summers AM, Read IR, Fairhust DA, Plant DJ, Campalani E, Smith CH, Barker JN, Detmar MJ, Brenchley PE, Griffiths CE (2006) Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol 126:453–459PubMedCrossRef
31.
Zurück zum Zitat Zittermann SI, Issekutz AC (2006) Basic fibroblast growth factor (bFGF, FGF-2) potentiates leukocyte recruitment to inflammation by enhancing endothelial adhesion molecule expression. Am J Pathol 168:835–846PubMed Zittermann SI, Issekutz AC (2006) Basic fibroblast growth factor (bFGF, FGF-2) potentiates leukocyte recruitment to inflammation by enhancing endothelial adhesion molecule expression. Am J Pathol 168:835–846PubMed
Metadaten
Titel
Angiogenic activity in patients with psoriasis is significantly decreased by Goeckerman’s therapy
verfasst von
C. Andrys
L. Borska
D. Pohl
Z. Fiala
K. Hamakova
J. Krejsek
Publikationsdatum
01.03.2007
Verlag
Springer-Verlag
Erschienen in
Archives of Dermatological Research / Ausgabe 10/2007
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-006-0723-8

Weitere Artikel der Ausgabe 10/2007

Archives of Dermatological Research 10/2007 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

16.04.2024 DGIM 2024 Nachrichten

Den Reflex, eine oberflächliche chronische Hautwunde ohne Entzündungszeichen in jedem Fall abzustreichen, sollte man nach einer neuen „Klug-entscheiden“-Empfehlung unterdrücken.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.